Olema Oncology's Participation in Healthcare Conference
Olema Pharmaceuticals, Inc. is set to make a significant appearance at a key industry event. The company, recognized for its focused efforts on breast cancer therapies, will be participating in the 8th Annual Evercore Healthcare Conference. This esteemed gathering will take place soon, and many are keen to hear the insights from Olema’s leadership.
Details on the Event
The company's fireside chat is scheduled for Wednesday, December 3, 2025, at 12:55 p.m. ET. This event presents a valuable opportunity for investors and stakeholders to gain deeper insights into Olema’s strategic direction, advancements, and future goals.
Investing in Tomorrow's Therapies
Olema Oncology specializes in developing innovative treatments aimed at improving the lives of patients affected by breast cancer. With their ongoing research, they are dedicated to discovering new therapies that could change standards of care in oncology.
Webcasts and Investor Access
For those unable to attend the live session, recordings and webcasts of the discussions will be accessible. Investors can find these materials in the Events and Presentations section of Olema’s investor relations website, ensuring they stay updated on the latest developments.
A Closer Look at Olema's Pipeline
One of the company's standout candidates is palazestrant (OP-1250), which is currently being evaluated in two Phase 3 clinical trials. This oral medication is designed to serve as both an estrogen receptor antagonist and a selective estrogen receptor degrader, making it a novel contender in the treatment of breast cancer.
Further Innovations
Additionally, Olema is working on OP-3136, a potent inhibitor of lysine acetyltransferase 6 (KAT6), now advancing through Phase 1 clinical studies. Such innovative research positions Olema Oncology at the forefront of clinical advancements in cancer treatment.
About Olema Oncology
Headquartered in San Francisco, Olema Oncology maintains a commitment to transforming treatment outcomes for breast cancer patients. Their innovative approach stems from a deep understanding of endocrine-driven cancers and mechanisms of treatment resistance.
Contact for Further Inquiries
For those interested in more information, Olema encourages reaching out to their media and investor relations team. Courtney O'Konek serves as the Vice President of Corporate Communications, and inquiries can be directed to media@olema.com.
Frequently Asked Questions
What is the purpose of Olema's participation in the conference?
Olema aims to share insights on its strategic initiatives and research developments in breast cancer treatment.
When will Olema's session take place?
The fireside chat is scheduled for December 3, 2025, at 12:55 p.m. ET.
How can one access the presentations?
Webcasts and recordings will be available on Olema's investor relations website after the event.
What are Olema's leading product candidates?
The leading candidate is palazestrant (OP-1250), currently undergoing Phase 3 trials, alongside OP-3136, a new KAT6 inhibitor in Phase 1 studies.
Who should I contact for more information?
Inquiries can be made to Courtney O'Konek at Olema Oncology via their media email address.
